Patient, donor, and graft characteristics
| Case . | Sex . | Age at Tx . | Diagnosis . | Disease status at Tx . | Cytogenetic/molecular abnormalities . | Donor . | No. of CD34+ infused (×106/kg) . | No. of CD3+ infused (×103/kg) . | CMV serology D/R . | Acute GVHD . | Chronic GVHD . | Relevant infections . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 16 y, 3 mo | BCP CD10+ ALL | 3rd CR | t(9;22) | mother | 20 | 12 | +/+ | Grade II | No | No | Alive, CR (+48 mo) |
| 2 | F | 3 y, 8 mo | BCP CD10+ ALL | 2nd CR | / | father | 29.1 | 6.8 | +/+ | No | No | CMV | Relapsed (+7 mo) dead |
| 3 | M | 20 y, 2 mo | AML (M2) | 3rd CR | t(8;21) del.9q | sister | 10.6 | 13 | +/+ | Grade I | No | BK cystitis, EBV, adenovirus, measles, fusarium | Alive, CR (+28 mo) |
| 4 | M | 10 y, 8 mo | AML (M0-M1) | 1st CR | / | mother | 12.2 | 35 | +/+ | No | No | No | Relapsed (+5 mo) dead |
| 5 | M | 4 y, 9 mo | BCP CD10+ ALL + | 2nd CR | / | mother | 21.9 | 17 | +/+ | No | No | No | Alive, CR (+14 mo) |
| 6 | F | 3 y, 9 mo | JMML | Disease present | PTPN11 mutation | mother | 23.7 | 30 | +/+ | Grade II | Limited | No | Alive, CR (+14 mo) |
| 7 | M | 14 y, 1 mo | AML (M0) | 1st CR | FTL3-ITD | sister | 16.1 | 2.9 | +/− | No | No | No | Relapsed (+3 mo) dead |
| 8 | M | 17 y, 2 mo | BCP CD10+ ALL | 2nd CR | / | brother | 23.0 | 4.5 | +/+ | No | No | CMV | Alive, CR (+11 mo) |
| 9 | M | 5 y, 7 mo | BCP CD10+ ALL | 2nd CR | t(9;22) | mother | 15.1 | 16 | +/+ | Grade II | No | No | Alive, CR (+54 mo) |
| 10 | F | 6 y, 4 mo | AML (M1) | Disease present | FTL3-ITD | mother | 31.7 | 14 | +/+ | No | No | No | Relapsed (+5 mo) dead |
| 11 | M | 4 y, 8 mo | T-ALL | 4th CR | / | father | 41.23 | 14 | −/+ | No | No | Candida spp, HHV6, EBV | Alive, CR (+24 mo) |
| 12 | F | 7 y, 1 mo | AML (M2) | 2nd CR | / | mother | 35.0 | 3 | +/+ | No | No | No | Alive, CR (+25 mo) |
| 13 | F | 5 y, 4 mo | BCP CD10+ ALL | 2nd CR | / | mother | 37.0 | 3 | +/+ | Grade II | Limited | No | Alive, CR (+23 mo) |
| 14 | M | 8 y, 5 mo | BCP CD10+ ALL | 2nd CR | / | sister | 11.6 | 19 | +/+ | No | No | No | Relapsed (+12 mo) alive |
| 15 | F | 4 y, 4 mo | BCP CD10+ ALL | 1st CR | / | mother | 19.5 | 1 | +/+ | Grade I | No | CMV, BK cystitis | Alive, CR (+17 mo) |
| 16 | F | 4 y, 1 mo | AML (M7) | 2nd CR | / | father | 22.3 | 2 | +/+ | No | n.e. | No | Relapsed (+3 mo) dead |
| 17 | M | 5 y | T-ALL | 4th CR | / | father | 32,1 | 5 | +/+ | No | No | No | Alive, CR (+24 mo) |
| 18 | M | 8 y, 2 mo | AML (M2) | 2nd CR | t(8;21) | mother | 38.6 | 3 | +/+ | No | No | No | Alive, CR (+22 mo) |
| 19 | M | 16 y, 1 mo | BCP CD10+ ALL | 3rd CR | / | mother | 18.4 | 0.5 | +/− | No | No | No | Relapsed (+4 mo) dead |
| 20 | F | 12 y, 10 mo | BCP CD10+ ALL | 2nd CR | t(9;22) | brother | 20.6 | 4 | +/+ | No | No | VZV | Alive, CR (+16 mo) |
| 21 | M | 11 y,11 mo | Secondary AML | 2nd CR | Complex karyotype | mother | 15.5 | 0.008 | +/+ | No | No | No | Alive, CR (+16 mo) |
| Case . | Sex . | Age at Tx . | Diagnosis . | Disease status at Tx . | Cytogenetic/molecular abnormalities . | Donor . | No. of CD34+ infused (×106/kg) . | No. of CD3+ infused (×103/kg) . | CMV serology D/R . | Acute GVHD . | Chronic GVHD . | Relevant infections . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 16 y, 3 mo | BCP CD10+ ALL | 3rd CR | t(9;22) | mother | 20 | 12 | +/+ | Grade II | No | No | Alive, CR (+48 mo) |
| 2 | F | 3 y, 8 mo | BCP CD10+ ALL | 2nd CR | / | father | 29.1 | 6.8 | +/+ | No | No | CMV | Relapsed (+7 mo) dead |
| 3 | M | 20 y, 2 mo | AML (M2) | 3rd CR | t(8;21) del.9q | sister | 10.6 | 13 | +/+ | Grade I | No | BK cystitis, EBV, adenovirus, measles, fusarium | Alive, CR (+28 mo) |
| 4 | M | 10 y, 8 mo | AML (M0-M1) | 1st CR | / | mother | 12.2 | 35 | +/+ | No | No | No | Relapsed (+5 mo) dead |
| 5 | M | 4 y, 9 mo | BCP CD10+ ALL + | 2nd CR | / | mother | 21.9 | 17 | +/+ | No | No | No | Alive, CR (+14 mo) |
| 6 | F | 3 y, 9 mo | JMML | Disease present | PTPN11 mutation | mother | 23.7 | 30 | +/+ | Grade II | Limited | No | Alive, CR (+14 mo) |
| 7 | M | 14 y, 1 mo | AML (M0) | 1st CR | FTL3-ITD | sister | 16.1 | 2.9 | +/− | No | No | No | Relapsed (+3 mo) dead |
| 8 | M | 17 y, 2 mo | BCP CD10+ ALL | 2nd CR | / | brother | 23.0 | 4.5 | +/+ | No | No | CMV | Alive, CR (+11 mo) |
| 9 | M | 5 y, 7 mo | BCP CD10+ ALL | 2nd CR | t(9;22) | mother | 15.1 | 16 | +/+ | Grade II | No | No | Alive, CR (+54 mo) |
| 10 | F | 6 y, 4 mo | AML (M1) | Disease present | FTL3-ITD | mother | 31.7 | 14 | +/+ | No | No | No | Relapsed (+5 mo) dead |
| 11 | M | 4 y, 8 mo | T-ALL | 4th CR | / | father | 41.23 | 14 | −/+ | No | No | Candida spp, HHV6, EBV | Alive, CR (+24 mo) |
| 12 | F | 7 y, 1 mo | AML (M2) | 2nd CR | / | mother | 35.0 | 3 | +/+ | No | No | No | Alive, CR (+25 mo) |
| 13 | F | 5 y, 4 mo | BCP CD10+ ALL | 2nd CR | / | mother | 37.0 | 3 | +/+ | Grade II | Limited | No | Alive, CR (+23 mo) |
| 14 | M | 8 y, 5 mo | BCP CD10+ ALL | 2nd CR | / | sister | 11.6 | 19 | +/+ | No | No | No | Relapsed (+12 mo) alive |
| 15 | F | 4 y, 4 mo | BCP CD10+ ALL | 1st CR | / | mother | 19.5 | 1 | +/+ | Grade I | No | CMV, BK cystitis | Alive, CR (+17 mo) |
| 16 | F | 4 y, 1 mo | AML (M7) | 2nd CR | / | father | 22.3 | 2 | +/+ | No | n.e. | No | Relapsed (+3 mo) dead |
| 17 | M | 5 y | T-ALL | 4th CR | / | father | 32,1 | 5 | +/+ | No | No | No | Alive, CR (+24 mo) |
| 18 | M | 8 y, 2 mo | AML (M2) | 2nd CR | t(8;21) | mother | 38.6 | 3 | +/+ | No | No | No | Alive, CR (+22 mo) |
| 19 | M | 16 y, 1 mo | BCP CD10+ ALL | 3rd CR | / | mother | 18.4 | 0.5 | +/− | No | No | No | Relapsed (+4 mo) dead |
| 20 | F | 12 y, 10 mo | BCP CD10+ ALL | 2nd CR | t(9;22) | brother | 20.6 | 4 | +/+ | No | No | VZV | Alive, CR (+16 mo) |
| 21 | M | 11 y,11 mo | Secondary AML | 2nd CR | Complex karyotype | mother | 15.5 | 0.008 | +/+ | No | No | No | Alive, CR (+16 mo) |
F indicates female; M, male; Tx, transplantation; BCP, B-cell precursor; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; JMML, juvenile myelomonocytic leukemia; CR, complete remission; FTL3-ITD, internal tandem duplication; D/R, donor/recipient; GVHD, graft-versus-host disease; n.e., not evaluable; EBV, Epstein-Barr virus; CMV, cytomegalovirus; HHV-6, human herpesvirus 6; BK, papillomavirus type BK; and VZV, varicella-zoster virus.